# US 2001/0027248 A1 · Novel receptor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0027248 A1
- Document ID: US20010027248A1
- Status: Published application
- Kind: A1
- Application number: 09/864,618
- Filed: 2001-05-24
- Published: 2001-10-04
- Earliest claimed: 1994-12-17
- Assignees: SmithKline Beecham Corporation
- Inventors: Hugh Jonathan Herdon; Jeffrey Clifford Jerman; Wai Ngor Chan
- Web page: https://patentgrep.com/patent/US20010027248A1

## CPC

- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- C07B 59/002: {Heterocyclic compounds}
- C07K 14/70571: {for neuromediators, e.g. serotonin receptor, dopamine receptor}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A receptor in substantially pure form obtainable from rat forebrain tissue which is characterized in that; a) compound A binds to it with a Kd of 40 nM for rat forebrain tissue, b) compound A binds to it with a Bmax of 220 pmol/g protein for rat forebrain tissue c) compound B binds to it with a Kd of 2 nM for rat forebrain tissue d) compound B binds to it with a Bmax of 220 pmol/g protein for rat forebrain tissue; and homologous receptors from other sources sharing at least 85% homology with the rat forebrain tissue.

## Claims

### Claim 1

A receptor in substantially pure form obtainable from rat forebrain tissue which is characterised in that;
a) compound A binds to it with a Kd of 40 nM for rat forebrain tissue,
b) compound A binds to it with a Bmax of 220 pmol/g protein for rat forebrain tissue
c) compound B binds to it with a Kd of 2 nM for rat forebrain tissue
d) compound B binds to it with a Bmax of 220 pmol/g protein for rat forebrain tissue;
and homologous receptors from other sources sharing at least 85% homology with the rat forebrain tissue.

### Claim 2 (depends on 1)

A soluble form of the receptor as defined in claim 1.

### Claim 3 (depends on 1)

A receptor as defined in claim 1 having a molecular weight in the region of 130 kiloDaltons when analysed by gel electrophoresis (SDS-PAGE).

### Claim 4 (depends on 2)

The use of a soluble form of the receptor as defined in claim 2 as a therapeutic agent.

### Claim 5 (depends on 2)

The use of a soluble form of the receptor as defined in claim 2 in the manufacture of a medicament for treating and/or preventing of anxiety, mania, depression, disorders associated with a subarachnoid haemorrhage or neural shock, the effects associated with withdrawal from substances of abuse such as cocaine, nicotine, alcohol and benzodiazepines, disorders treatable and/or preventable with anti-convulsive agents, such as epilepsy; Parkinson's disease, psychosis, migraine and/or cerebral ischaemia.

### Claim 6 (depends on 2)

A method of treating and/or preventing anxiety, mania, depression, disorders associated with a subarachnoid haemorrhage or neural shock, the effects associated with withdrawal from substances of abuse such as cocaine, nicotine, alcohol and benzodiazepines, disorders treatable and/or preventable with anti-convulsive agents, such as epilepsy; Parkinson's disease, psychosis, migraine and/or cerebral ischaemia, which comprises administering an effective or prophylactic amount of the soluble receptor as defined in claim 2 to a sufferer in need thereof.

### Claim 7 (depends on 2)

A pharmaceutical composition for use in the treatment or prevention of anxiety, mania, depression, disorders associated with a subarachnoid haemorrhage or neural shock, the effects associated with withdrawal from substances of abuse such as cocaine, nicotine, alcohol and benzodiazepines, disorders treatable and/or preventable with anti-convulsive agents, such as epilepsy Parkinson's disease, psychosis, migraine and/or cerebral ischaemia, which comprises the soluble receptor as defined in claim 2 admixed with pharmaceutically acceptable carriers.

### Claim 8 (depends on 1)

A method of screening compounds having therapeutic activity associated with binding to the receptor as defined in claim 1 which comprises; contacting a test compound with a substrate in which the novel receptor is present and measuring the degree of binding.

### Claim 9 (depends on 1, 8)

A radio-labelled compound which binds to the receptor as defined in claim 1 and may be displaced using the method of screening as defined in claim 8.

### Claim 10 (depends on 8)

A novel compound and pharmaceutically acceptable salts, hydrates or solvates thereof identified in the screening method as defined in claim 8.

### Claim 11 (depends on 10)

The use of a compound of claim 10 or a pharmaceutical acceptable salt, hydrate or solvate thereof as a therapeutic agent.

### Claim 12 (depends on 10)

A method of treating or preventing disorders which comprises administering an effective and/or prophylactic amount of a compound as defined in claim 10 or a pharmaceutically acceptable salt, hydrate or solvate thereof to a sufferer in need thereof.

### Claim 13 (depends on 10)

The use of a compound as defined in claim 10 in the manufacture of a medicament for treating or preventing anxiety, mania, depression, disorders associated with a subarachnoid haemorrhage or neural shock, the effects associated with withdrawal from substances of abuse such as cocaine, nicotine, alcohol and benzodiazepines, disorders treatable and/or preventable with anti-convulsive agents, such as epilepsy, Parkinson's disease, psychosis, migraine and/or cerebral ischaemia.

### Claim 14 (depends on 10)

A pharmaceutical composition for use in treating or preventing anxiety, mania, depression, disorders associated with a subarachnoid haemorrhage or neural shock, the effects associated with withdrawal from substances of abuse such as cocaine, nicotine. alcohol and benzodiazepines. disorders treatable and/or preventable with anti-convulsive agents, such as epilepsy, Parkinson's disease, psychosis, migraine and/or cerebral ischaemia, which comprises admixing a compound as defined in claim 10 with a pharmaceutically acceptable carrier.

### Claim 15 (depends on 1)

A monoclonal or polyclonal antibody which binds to the receptor as defined in claim 1.

### Claim 16 (depends on 15)

The use of a monoclonal or polyclonal anti-body as defined in claim 15 which binds to the novel receptor as a therapeutic agent.

### Claim 17 (depends on 15)

The use of a monoclonal or polyclonal antibody as defined in claim 15 which binds to the novel receptor in the manufacture of a medicament for treating and/or preventing anxiety, mania, depression, disorders associated with a subarachnoid haemorrhage or neural shock, the effects associated with withdrawal from substances of abuse such as cocaine, nicotine, alcohol and benzodiazepines, disorders treatable and/or preventable with anti-convulsive agents, such as epilepsy; Parkinson's disease, psychosis, migraine and/or cerebral ischaemia.

### Claim 18 (depends on 15)

A method of treating and/or preventing of anxiety, mania, depression, disorders associated with a subarachnoid haemorrhage or neural shock, the effects associated with withdrawal from substances of abuse such as cocaine, nicotine, alcohol and benzodiazepines, disorders treatable and/or preventable with anti-convulsive agents, such as epilepsy Parkinson's disease, psychosis, migraine and/or Cerebral ischaemia, which comprises administering an effective and/or prophylactic amount of a monoclonal or polyclonal anti-body as defined in claim 15 which binds to the novel receptor.

### Claim 19 (depends on 15)

A pharmaceutical composition for use in treating and/or preventing anxiety, mania, depression, disorders associated with a subarachnoid haemorrhage or neural shock, the effects associated with withdrawal from substances of abuse such as cocaine, nicotine, alcohol and benzodiazepines, disorders treatable and/or preventable with anti-convulsive agents, such as epilepsy; Parkinson's disease, psychosis, migraine and/or cerebral ischaemia, which comprises admixing a monoclonal or polyclonal anti-body as defined in claim 15 with a pharmaceutically acceptable carrier.

### Claim 20 (depends on 1)

A radioactively-labelled compound which binds to the novel receptor as defined in claim 1.

### Claim 21 (depends on 1, 20)

The use of radio-labelled compounds as defined in claim 20 which binds to the novel receptor as diagnostic tools for detecting changes or abnormalities in the novel receptor as defined in claim 1.
